PMA assessment has been proposed to be a superior marker of platelet activation compared with surface P-selectin, and preclinical studies in mice have suggested that targeting PMA may yield therapeutic benefit because these aggregates play a crucial role in inducing endothelial dysfunction and consequent atheroma formation (58). This evidence concerns the gene SELP and endothelial dysfunction.